MODV vs. LFMD, ACB, ANRO, TERN, ANIK, CERS, ORGO, SLDB, AMRN, and AURA
Should you be buying ModivCare stock or one of its competitors? The main competitors of ModivCare include LifeMD (LFMD), Aurora Cannabis (ACB), Alto Neuroscience (ANRO), Terns Pharmaceuticals (TERN), Anika Therapeutics (ANIK), Cerus (CERS), Organogenesis (ORGO), Solid Biosciences (SLDB), Amarin (AMRN), and Aura Biosciences (AURA). These companies are all part of the "medical" sector.
LifeMD (NASDAQ:LFMD) and ModivCare (NASDAQ:MODV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
ModivCare has a net margin of -8.02% compared to ModivCare's net margin of -14.75%. LifeMD's return on equity of 34.93% beat ModivCare's return on equity.
35.5% of LifeMD shares are owned by institutional investors. 18.9% of LifeMD shares are owned by insiders. Comparatively, 10.9% of ModivCare shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
LifeMD has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, ModivCare has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
LifeMD has higher earnings, but lower revenue than ModivCare. LifeMD is trading at a lower price-to-earnings ratio than ModivCare, indicating that it is currently the more affordable of the two stocks.
In the previous week, LifeMD had 2 more articles in the media than ModivCare. MarketBeat recorded 4 mentions for LifeMD and 2 mentions for ModivCare. LifeMD's average media sentiment score of 0.63 beat ModivCare's score of 0.44 indicating that ModivCare is being referred to more favorably in the news media.
LifeMD received 12 more outperform votes than ModivCare when rated by MarketBeat users. Likewise, 70.27% of users gave LifeMD an outperform vote while only 40.00% of users gave ModivCare an outperform vote.
LifeMD presently has a consensus price target of $11.60, indicating a potential upside of 49.29%. ModivCare has a consensus price target of $49.25, indicating a potential upside of 79.03%. Given LifeMD's higher probable upside, analysts clearly believe ModivCare is more favorable than LifeMD.
Summary
LifeMD beats ModivCare on 11 of the 18 factors compared between the two stocks.
Get ModivCare News Delivered to You Automatically
Sign up to receive the latest news and ratings for MODV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MODV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ModivCare Competitors List
Related Companies and Tools
